Quantum Dots: Targeted and Traceable Drug Delivery System

 

Vignesh Saravanan, Vamshi Krishna Tippavajhala*

Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences,

Manipal Academy of Higher Education, Manipal, Karnataka, India.

 

ABSTRACT:

“Quantum dots (QD’s) are semiconductor crystals of nanometre dimensions with distinctive conductive properties determined by its size”. If the semiconductor particle area unit is created sufficiently small, quantum effects get to play. When UV light hits these conductive nanoparticles, they will emit light of varied colors and these colors will be varied by dominant the dimensions of nanoparticles. Traditional imaging models like MRI andPET are less sensitive compared to optical imaging done using QD’s which is significantly cheaper, cost-effective and shortens the time required for drug development. Earlier QD’s were cadmium based which provides it with unique photonic properties and photonic stability but because of its toxicity, it is replaced with alternative materials like germanium, silicon and carbon. The structure of QD’s contains a core that is a structural scaffold and imaging distinction agent. Small hydrophobic molecules can be embedded in between the inorganic core and amphiphilic polymer coating layer, hydrophilic agents can be immobilized in the hydrophilic end of the amphiphilic polymer through covalent and non-covalent bonds. This kind of nanostructures acts as a magic bullet that not solely identifies, binds to the targeted unhealthy cells however additionally emits detectable signals that help in the real-time tracking.

 

 

 

INTRODUCTION:

Quantum Dots are Nanocrystals which when hit with a UV light semiconductor nanoparticle can emit light of various colors. In the 1970s and 80’s the theory of Nanoparticles Semiconductor quantum was first proposed. According to the theory, if the semiconductor is made small enough, quantum effects are seen which constricts the energies at which electrons and holes (absence of electrons) can exist in the particles. Since the energy can be constricted the optical property of the particle also can be made according to the size of the quantum dots. The Quantum dots helps to study cell processes at the single-molecule level. These are used in the diagnosis and treatment of diseases such as cancer. QDs' atom-like energy states also contribute to unique optical properties, such as a particle-size-dependent fluorescence wavelength, which is useful in the fabrication of optical probes for biological and medical imaging. Because of their small size, dots can be used in a variety of biomedical applications, including medical imaging, biosensors, and so on. Fluorescence-based biosensors currently rely on organic dyes with a wide spectral range, limiting their ability to tag agents to a small number of colors and shorter lifetimes. Quantum dots, on the other hand, can emit the entire spectrum, are brighter and degrade less over time than traditional organic dyes used in biomedical applications, proving their superiority. As biological chromophores, various highly fluorescent QDs of elements of groups II-IV, such as CdSe and CdS, with wavelength-tunable emission have been used. The use of CdSe QDs, on the other hand, is problematic due to their toxicity. For biological applications, nontoxic or less toxic QDs that can replace Cd-based QDs are needed.

 

Quantum Dot¹:

QDs are crystalline semiconductors with a diameter of lesser than 10 nm that have been reported. “II-VI, IV-VI, or III-V semiconductors are used to make the highest-quality QDs”. A thin, insulating ZnS shell surrounds a CdSe core is the most typical QD structure (both II-VI materials). The final Quantum dots are lipophilic and should be moved into aqueous solutions before biological usage due to a surface monolayer coating of nonpolar coordinating ligands left over from synthesis. This is achieved by using a bifunctional ligand to replace the hydrophobic surface molecule or by covering the hydrophobic surface with a polymer to shield it from the external aqueous environment. QD imaging probes have long-term photo stability, allowing researchers to study the dynamics of cellular processes over time, such as monitoring cell migration, differentiation, and metastasis in real time. Because of these properties, QDs have become a hot topic in cancer imaging, molecular profiling, and cancer biology.

 

Designing of Quantum dot²:

In general, before being used in biological systems, hydrophobically synthesised Quantum Dots must be moved to an aqueous process. The hydrophobic surface ligands can be replaced with bifunctional ligands or the entire Quantum Dots can be coated with an amphiphilic polymer layer to achieve this. In vivo targeting experiments in nude mice of human prostate cancer show that this class of Quantum Dots probes can be delivered to cancer cells through the EPR effect as well as antibody binding to cancer-specific cell-surface markers.

 

This sturdy design enables broad range of targeting ligands, such as antibodies, peptides, and small molecules, to be attached. The technique for binding molecule to the outer layer, on the other hand, must be carefully considered. The multivalency effect, in which huge proportion and/or unique combos of targeting molecules per Quantum Dots surface increase affinity, can be used to achieve better in-vivo targeting. Although the conceptual model and findings of Virus polyvalency, cell signalling, and all of these methods of lymphocyte localization offers a potentials, engineers should continue to battle a number of obstacles before they can use this phenome-non. For reference, current conjugation methods produce nanoparticle probes with a broad range of targeting ligands per particle. Furthermore, since the exact orientation and conformation of the targeting ligand is often uncertain, a portion of the probe is likely to be non-functional.

 

While optical imaging is highly sensitive, it is limited in its application in vivo and in humans due to a lack of anatomic resolution and spatial information. “Although near-infrared wavelengths can increase penetration depth and 3D fluorescence tomography can provide spatial information, other imaging modalities, such as MRI, are better suited to tomography and 3D imaging. As a result, there's been a lot of interest in developing dual-modality contrast agents for combined optical and MR imaging, which has excellent tissue contrast and spatial resolution and is commonly used in clinical practise. Dual magneto-optical probes that attach to apoptotic cells and can be detected using fluorescence and magnetic resonance imaging. Peptides are conjugated to cross-linked iron oxide amines (amino–CLIO) through a disulfide or thioether linker, then the dye Cy5 or Cy7 is attached”.

 

Nanoparticles often have a variety of surface functional groups that can be used to chemically conjugate diagnostic and therapeutic agents. As a result, “multifunctional nanostructures that can be used for tumour imaging and treatment at the same time can be designed and created. However, progress has been slow, and promising multifunctional platforms such as dendrimers, liposomes, and PEBBLES (probes encapsulated in biologically localised embedding) are still in the ‘proof-of-concept' stage, utilising cultured cancer cells that aren't immediately applicable to in vivo imaging and solid tumour treatment”.

 

Figure1: Structure of Quantumn dots Nanocrystal

 

Types of Quantum dots: Following are the various types of quantum dots:

I.      Cadmium Quantum Dots³:

Cadmium-containing quantum dots (Cd-QDs) have drawn a lot of interest for drug delivery in biomedicine because of their unusual optical properties and flexible surface chemistry. The unknown biological fate and possible toxicity, Cd-QD applications are currently confined to cells and small animals. As a result, to improve therapeutic applications of Cd-QDs as nanomedicines, the long-term fate of Cd-QDs and their interaction with biological systems must be investigated. Living systems, cells, and biomacromolecules are all examples of biological systems. Furthermore, the emphasis was placed on examining the similarities and differences in their toxicological results at all three levels to fully interpret the potential carcinogenicity of Cd-QDs and fully comprehend the mechanism involved.”

 

II.   Graphene Quantum Dots^4,5:

GQDs (graphene quantum dots) are small graphene fragments with confined electronic transport in all three spatial dimensions. Graphene is a semiconductor with a zero bandgap and an infinite exciton Bohr diameter. As a result, confinement can be observed in any fragment; however, GQDs are typically smaller than 20 nm in diameter. The main disadvantages of colloidal semiconductor QDs are their inherent toxicity (for example, in the case of the widely used CdSe QDs) and the fact that they are colloids, which makes chemical coupling difficult and causes colloidal stability issues in many applications. GQDs are much easier to handle than colloidal QDs because they have a more "molecule-like" character, are non-toxic, and exhibit the desirable electro-optic properties of quantum dots.”

 

Synthesis of Graphene Quantum Dots (GQD’s):^4,6

The current technique for GQD synthesis can be classified into two groups, top-down and bottom-up processes. GQD synthesis, including bottom-up processes, necessitates sophisticated reaction steps and special organic materials, making it even harder to enhance the situation. As a result, the top-down method, which involves cutting tiny bits from big chunks of carbon materials, is preferred. The method requires large quantity of carbon materials that are low cost and simple to acquire, as well as a method that is comparatively simple and easy to synthesize GQDs.

 

III. Silicon Quantum Dots:^7,8

Si QDs are nontoxic, and the silicic acid formed during their degradation is easily excreted in the urine. Si-QDs can also emit light in the infrared range, making them useful for penetrating deep tissues. Fabrication of Si QDs that can be spread in water is important for Si QDs to be used in biological applications. It has been difficult to render water-dispersible Si-QDs that continue to display size-dependent photoluminescence (PL) when immersed in water. When the crystal diameter of silicon is reduced to less than the bulk-Si exciton Bohr radius, which is approximately 4 nm, it exhibits remarkable improvements in optical properties. Si QDs are a promising material for a wide range of applications, including optoelectronic devices and bioimaging fluorophores, thanks to their optical properties.”

 

Synthesis of Silicon Quantum Dots:^7,8

A.  Physical Routes to Synthesizing SiQDs

a)    Laser Generation

b)    Plasma Synthesis

B.   Chemical Routes to Synthesizing SiQDs

a)    Electrochemical Etching

b)    Zintl Salt Oxidation

c)     Reduction of Silicon Halides

d)    Decomposition of Si-containing Precursors

e)     Template Synthesis

 

DRUG FORMULATIONS FOR TARGETED DELIVERY⁹:

Quantum dots offer a comprehensive foundation for building traceable drug delivery systems with the opportunities to enhance patient outcomes to transform cancer treatment pharmacologically. In order to develop QD/drug nanoparticle preparations for targeted therapy in vivo, certain rules should be followed:

i.       The drug must be delivered along with the carrier and the nanoparticle surface must be functionalized with targeting ligands for precise delivery to tumor cells.

ii.     To allow excretion from the body, the nanoparticle's size must be minimized.

iii.    To avoid any adverse effects on normal tissue, the drug molecules must be retained within the nanoparticle delivery system; however, the drug must be released at tumour cells after being activated externally or by local environmental factors.

iv.   To avoid degradation or deterioration of QDs as they come into contact with the biological environment, their surfaces must be passivated with a long-lasting biocompatible polymer.”

 

Two approaches can be used to integrate QDs and drug molecules into a nanoparticle formulation:

a.     delivery of drug-conjugated QDs to specific sites and subsequent release of drug molecules from the QD surface in response to local biological conditions such as pH or the presence of enzymes; conjugating or connecting drug molecules to the QD surface, accompanied by delivery of drug-conjugated QDs to specific sites and subsequent release of drug molecules from the QD surface in response to local biological conditions such as pH or the presence of enzymes;

b.     depending on the type of polymer particle used to encapsulate them, loading the drug in a polymer nanoparticle system that also contains either hydrophobic or hydrophilic QDs. The entire QD/drug nanoparticle system is delivered to the desired organ or tissue, and the drug molecules are released either when the polymer particle degrades at low pH or when the polymer particle diffuses out.”

 

The first approach was used by Bagalkot et al., who demonstrated the synthesis of QD-aptamer (Apt)doxorubicin (Dox) conjugates (QD-Apt (Dox)) as a complex conjugate for targeted cancer imaging, treatment, and sensing. The QD surface was functionalized with an RNA aptamer that recognizes the extracellular domain of the prostate-specific membrane antigen, allowing prostate cancer cells to be targeted and imaged more effectively. Dox, an anticancer drug intercalated with an RNA aptamer, is slowly released from the QD system.

 

Figure 2: Targeted drug delivery using quantum dots

 

The Forster (fluorescence) resonance energy transfer (FRET) between QD and Dox was used to monitor the drug's release. This device could deliver Dox to prostate cancer cells and detect Dox delivery by activating the fluorescence of QDs that were imaging the cancer cells at the same time. This nanoparticle conjugate formulation's specificity and sensitivity as a cancer imaging, treatment, and sensing device were demonstrated in vitro.

 

Mahajan et al. used an appealing approach in which a QD-based platform was used to combine drug delivery with site-specificity. Carbodiimide chemistry was used to conjugate the antiretroviral drug saquinavir and the biorecognition molecule transferrin (Tf) to carboxyl-terminated quantum dots. This study aimed to improve saquinavir transport into the brain for the treatment of HIV-1 infected cells inside the brain by targeting the transferrin receptors (TfRs), which are overexpressed on the apical surface of the blood-brain barrier (BBB).They demonstrated that these targeted and drug-doped QDs can efficiently cross the BBB and cause a substantial reduction in viral replication in HIV-1 infected peripheral blood mononuclear cells (PBMCs) within the brain using an in vitro model of the BBB. These findings indicate that this nanoformulation can treat Neuro-AIDS and other neurological disorders.”

 

Encapsulating luminescent QDs with an ABC triblock copolymer and linking this amphiphilic polymer to tumor-targeting ligands and drug-delivery functionalities is part of the structural design. In vivo targeting experiments in nude mice with human prostate cancer show that the QD probes accumulate at tumors due to increased permeability and retention of tumor sites, as well as antibody binding to cancer-specific cell surface biomarkers. We achieved sensitive and multicolor fluorescence imaging of cancer cells in vivo using both subcutaneous injection of QD-tagged cancer cells and systemic injection of multifunctional QD probes. For efficient background removal and precise delineation of weak spectral signatures, a whole-body macro-illumination method with wavelength-resolved spectral imaging was combined. These findings open up new opportunities for in vivo ultrasensitive and multiplexed imaging of molecular targets.

 

The lack of tracking ability makes it difficult to evaluate interaction of liposomes with biological materials and, as a result, to design reasonable physical and chemical properties for this nanoparticle. Linking Quantum Dots to the liposome surface, transferring them into the core, or attaching them into the hydrophobic core are all viable options for visualizing the nanocarrier with less or no changes to the liposome properties.

 

Quantum Dots offer the unique capability of detecting not just the drug transporter, but also the dynamics of degradation process and load release, tissue/tumor infiltration, and clearance by limiting the minimum core size to around 2–5 nm. Individual nanoparticles cores released from deteriorated drug delivery carriers are excreted and extravasated normally within the 5.5 nm renal passage limit and 5–10 nm vasculature junctions, while intact nano-vehicle remain in blood stream and promote tumor deposition through the EPR mechanism. In the mean time, the significant size dependency of diffusive transport through an intermediate area makes it difficult to transmit huge complexes to chosen cells even after they have accumulated inside the tumor, necessitating nanovehicle degradation and drug release. Quantum Dots are excellent for determining site-uniqueness and drug release kinetics, evaluating medication penetration into the tumour, and tracking NP clearance in this regard.”

 

Table1: Marketed formulation of Quantum dots

 

Figure 3: QD-Apt (Dox) Bi-FRET system

 

 

Figure 4: Specific uptake of QD-Apt (Dox)

 

 

Tracing and drug release sensing property of Quantum Dots^10,11

High-quality nanocomposite Quantum Dots Radiates photons having a short wavelength and a restricted spectral range that is directly proportional to the size of the nanoparticle core. In the mean-time, Quantum Dots absorb light effectively over a broad range of wavelengths, from UV to the particle's emission wavelength. With the help of these combo characteristics using a single-source excitation, we were able to image and identify multicolor QDots simultaneously (e.g., UV lamp), opening up the possibility of tracking several nanovehicles within the same biological system and comparing their functionality under the same testing parameters. Some other set of QDot attributes that can be used to track nanocarriers throughout time is their enhanced brightness combined with photodegradation resistance. While organic fluorophores, which are often utilized as optical labels to visualize a number of drug delivery carrier are too faint to be effective allow recognition with a great specificity and suppress swiftly under constant irradiation, affecting long-term tracking, properly inactivated and layered Quantum Dots maintain nearly maximum fluorescent intensity constant for more than 30min, enabling for accurate imaging. Microenvironmental sensing could provide crucial information for identifying complex changes linked to nanocarrier cell binding, absorption, and intracellular drug release. Simultaneously, drug concentration sensing within the nanocarrier allows for drug loading efficiency assessment and real-time monitoring of drug release. Via fluorescence resonance energy transfer (FRET)¹², Quantum Dots allow such sensing functionality Organic dye FRET pairs, on the other hand, suffer from instability and photo bleaching. As a result, Quantum Dot-dye and Quantum Dot-quencher combinations have risen to the top of the rankings which provides us an options for studying complex microenvironmental shifts, nanocarrier degradation, and drug unloading. Notably, increases in Quantum Dot and organic dye fluorescence levels are directly correlated with nanocarrier degradation and cargo release, allowing for not only intracellular drug delivery monitoring but also real-time drug release kinetics measurement.

 

The Quantum Dot core's high electron density allows transmission electron microscopy(TEM) to detect individual NPs within intracellular compartments. Quantum Dot of different types can be differentiated by size with TEM and by chemical composition with ESI, allowing multi-NP studies at high resolution, similar to multicolor fluorescence microscopy. Quantum Dots can also be identified by a comprehensive investigation since they are made up of chemical elements that are found in limited concentration in biological samples (such as Cd2+).

 

Figure 3 shows schematic illustration of QD-Apt (Dox) Bi-FRET system¹³. Initially surface of CdSe/ZnS core-shell QD is modified with the A10 PSMA aptamer. Complexation of Dox within the A10 PSMA aptamer on the surface of QDs leads to the formation of QD-Apt (Dox) and reduction in fluorescence of both QD and Dox(“OFF” state).”

 

Figure 4 depicts schematic illustration of specific uptake of QD-Apt (Dox)¹³ coupling to the target tumour cell through PSMA-mediate endocytosis. The release of Dox from the QD-Apt (Dox) adducts causes the recovery of fluorescence of both QD and Dox (the “ON” state), allowing the synchronised fluorescent identification and death of tumor cells to be detected.”

 

Drug delivery with traceable nanocarriers:^5,10,14

Because the majority of chemotherapy medicines failure owing to pharmacokinetic issues, integrating these drugs into nanocarriers to change their pharmacokinetic properties is a simplest way to improve current cancer therapies. While techniques such as HPLC or depending on the inherent fluorescence of low molecular weight drugs have been used to test nanocarrier localization in vitro and in vivo, these techniques take longer time to complete and investigation is only possible to post mortem.

 

At both the subcellular and system level, several tracer reagents were utilised to detect nano drug delivery carriers., including magnetic nanoparticles, gold nanoparticles, radioisotopes, and organic fluorophores. Quantum Dots have become It's becoming more and more important to build sophisticated small-molecule nanocarriers that deliver drugs in a targeted and detectable manner, particularly in cellular studies, among these contrast agents.

 

Through an acid-sensitive coupler, drugs were covalently attached to the carrier system that only destroyed at the pH inside the cell, preventing systemic toxicity from early drug release into the blood stream. Although multifunctional Nanosystems can outperform early chemotherapeutic–NPs by a factor of ten, this carrier only resulted in minor improvements in cancer-specific cytotoxicity. Nanocarrier optimization could be accomplished by comparing the rates of cellular uptake in different cells across many formulations using real-time and quantitative Quantum Dot analysis.

 

Continuous Monitoring of siRNA and DNA delivery^10,11:

Many neurodegenerative diseases are marked by the accumulation of abnormal proteins, such as beta-amyloid peptide (Aβ) in Alzheimer's disease or super-oxide dismutase mutations in Amyotrophic Lateral Sclerosis (ALS) (ALS). Small RNA interference is thought to regulate normal neural growth and maintenance by suppressing the activation of abnormal genes.

 

In biological science, DNA and, in particular, short-interfering RNA (siRNA)¹⁵ Therapies have proven to be effective method for determining gene activity, and they have a lot of promise for treating human diseases. Gene-related treatments give higher efficacy and selectivity by targeting particular oncogenes and abnormal signaling pathways in cancer, while traditional chemotherapeutics work uniformly against both normal and cancerous cells. The uniformity of gene silencing within a cell population is a critical problem when using RNA interference to detect genotype/phenotype similarities. Variations in transfection effectiveness, delivery-induced cytotoxicity, and ‘off target' effects at high siRNA concentrations can all make functional studies difficult to interpret. To address this problem, we created a new method of monitoring siRNA delivery that combines unmodified siRNA with multicolor biological probes made of semiconductor quantum dots (QDs).

 

The intracellular and systemic distribution of NP has been linked to gene knockdown efficacy, cytotoxicity, and immunogenicity using QDots. siRNA/DNA drugs can be stuffed into an NP center using cationic lipids (lipoplexes) and polymers (polyplexes), or they can be directly conjugated or electrostatically bound to the surface of a Nano scaffold. Even at low concentrations, biological agents like siRNA have a high potency and catalytic activity, despite the poor loading ability of small-molecule lipophilic drugs on NP surfaces. Since the nanocarrier protects the siRNA/DNA from nuclease deterioration, it's crucial that complicated siRNA/DNA stays stable in blood circulation but dissociates from the nanocarrier intracellularly for successful gene knockdown/expression. In the area of siRNA/gene delivery, quantitative QDot-based FRET estimations are used to achieve the right balance in drug nanocarrier bonding in vitro, similar to small-molecule drug delivery. In vivo imaging of siRNA delivery carrier would be beneficial for assessing their efficiency based on parameters of the system such as half-life of the blood and sufficient tissue distribution, in addition to in vitro studies.”

 

In vivo Imaging:^5,10,11,16

QDs have been commonly used as in vivo imaging agents, in addition to their use as nanoprobes and labels for in vitro imaging. The most popular QDs agent for tumor-targeted imaging is a cancer-specific antibody combined with near-IR QDs with polymer coatings. However, due to the depth of the targets, in vivo imaging of QDs is complex. QDs with low toxicity, high contrast, high sensitivity, and photostability are needed for this application. Michalet's research showed that CdSe/ZnS QDs can visualize blood vessels in live mice with high contrast and imaging depth in two-photon excitation confocal microscopy. They reported that coatings on the surfaces of QDs, such as PEG, could reduce their toxicity and accumulation in the liver even more. According to some studies, increasing the length of the PEG coating polymer on the surface of QDs could slow down their extraction toward the liver, so coating polymer on the surfaces was another consideration to consider when using QDs for in vivo imaging.

 

Much attention has been focused on developing spherical QD conjugations as biological fluorescent markers, whether in vitro or in vivo, but there are few studies on how other morphologies of QDs can interact with biological systems¹⁸. CdSe/CdS/ZnS quantum rods (QRs) coated with PEGylated phospholipids and RGD peptide for tumor targeting were reported by Yong et al. This conjugation was shown to be a bright, photostable, and biocompatible luminescent probe for early cancer diagnosis, and it was thought to open up new imaging possibilities for early tumor development.”

 

Energy transfer mechanisms:

The intense attraction of QDs to the biosensing population is due to the photon-induced energy transfer phenomenon.

1.     Forster resonance energy transfer (FRET):¹⁶

FRET, whose principle is well established, is used in a large number of tests and bioprobes. FRET is a technique that involves the transfer of energy between two light-sensitive molecules. QDs are based on photon absorption that allows non-radiative energy transfer from the excited state to the ground state of acceptor chromophores in close proximity. Long-range dipole-dipole coupling enables QDs to transfer their excitonic energy to a nearby or electrostatically attached acceptor chromophore in a non-radiative manner. The resulting module illustrates how FRET can be used as an analytical signal. The fluorescence shift obtained is a sign that biomoieties have been added to QDs and can thus be used as probes. Unlike organic fluorophores, QDs have narrow emission and wide absorption, with no overlap of donor and acceptor absorption spectra, making them suitable and excellent candidates for FRET applications. The association or dissociation of acceptors and donors may also be influenced by biorecognition events on the surface of QDs.

 

2.     Chemiluminescence resonance energy transfer (CRET):^16,17

Optical excitation was used in FRET experiments to create an excited state donor capable of transferring energy to a ground state acceptor, resulting in fluorescence. The energy requirement came from in-situ chemical reactions that created excited state donors. The FRET principle can be used to describe or manipulate the efficiency of energy transfer once the excited state donor has been formed from these chemical reactions. Due to their strong excitation spectra, large Stoke's shifts, and size-dependent emission, QDs are well-matched fluorescent acceptors in CRET processes. Multiplex research has also been made possible by the use of QD-acceptors with different emission wavelengths that can be excited by the same chemiluminescent (CL) donors. CL can occur when target compounds are directly oxidized to create emitting species.” The oxidation of a luminescent donor occurs in QD-based CRET, and there are three potential mechanisms.”

·       After direct oxidation, QDs become emitter species. As chemically generated excitons relax in the presence of radiant energy, direct QD-CL occurs.

·       In reactions involving other fluorophores, QDs serve as catalysts (luminescent molecules).

·       After CRET, QDs can act as emitter species.

 

3.     Bioluminescence resonance energy transfer (BRET):^16,17

BRET is a naturally occurring mechanism in which a light-emitting protein passes its energy non-radiatively to a nearby acceptor molecule. QDs' wide absorption spectra enable them to be excited by nearly all bioluminescent proteins, and their unique properties (broad excitation and size tuneable emission) allow them to form a large number of QD-BRET pairs. For multiplexed BRET imaging, the bioluminescent protein Luc8 can be combined with QD605, QD655, QD705, and QD800. Upon conjugation, each of these exhibits productive BRET and can be imaged in vivo after injection. In terms of biosensing and in vivo imaging, CRET and BRET are potentially superior to FRET. Since CRET and BRET are so unique, they produce very low background emissions even in complex samples. BRET and CRET make it easy to observe light-sensitive tissues.

 

CONCLUSION:

In the field of nanomedicine, the production of novel nanoplatforms for disease diagnosis and treatment will continue to receive a lot of attention. We hope that some of the issues discussed in this special issue will provide readers and researchers with valuable knowledge to help them design better pharmaceutical products for human welfare. None of the methods for generating a homogeneously silenced population are as simple, modular, or flexible as RNAi delivery (co-delivery of fluorescent protein-expressing plasmids, end-labeling with a dye). Multicolor QD labels can be used interchangeably, with all particle sizes employing a common, passive mechanism to shape distribution complexes, in addition to superiority overdyes in brightness and photostability. Although it is unknown when a cell's RNAi machinery reaches saturation, this capability simplifies existing strategies for enriching for dual gene knockdowns using antibiotic-resistant markers that are co-transfected, transcribed, and picked. They were less toxic and had the same biological impact as the parental alminoprofen. These findings indicate that drug conjugation with biocompatible Si-QDs may be a viable approach for developing functional pharmaceutical drugs. Our study is a first step toward the development of novel Si drugs that improve the drug's functionality. More research is required to understand the underlying mechanisms, with goals like optimizing the surface modification and regulating particle size, as well as extending to in vitro and in vivo studies with dose and time response assessments. GQDs have been designed and synthesized to improve or optimize properties such as water solubility, optical absorption, and conductivity, among others. Graphene application has progressed slowly since its discovery. This is believed to be due to some of graphene's functional issues, such as its zero bandgap and low absorptivity. As a result, GQD production has become a critical catalyst for graphene application. GQDs are rapidly becoming important functional materials with applications in medicine, optics, and electricity. Drug delivery, sensors, and bio-imaging are only a few of the places where QDs may be useful. Several problems, such as overall toxicity, body clearance, synthesis protocol scalability, environmental effects, manufacturing costs, and so on, must be addressed before QDs can be realistically converted into clinical applications. The ranostic platforms are constantly being built by combining QDs with other types of nanoparticles and/or biologically active molecules. This study summarises the most recent findings in the literature on the use of QDs in medical applications.”

 

REFERENCES:

1.   Zunger A. Semiconductor quantum dots. MRS Bulletin-Materials Research Society. 1998 Feb 1; 23(2):15-7. doi.org/10.2217/17435889.1.2.209.

2.   Rhyner MN, Smith AM, Gao X, Mao H, Yang L, Nie S. Quantum dots and multifunctional nanoparticles: new contrast agents for tumor imaging. doi.org/10.2217/17435889.1.2.209.

3.   Wang J, Liu R, Liu B. Cadmium-containing quantum dots: current perspectives on their application as nanomedicine and toxicity concerns. Mini Reviews in Medicinal Chemistry. 2016 Jul 1; 16(11): 905-16.doi.org/10.2174/1389557516666160211121247.

4.   Tian P, Tang L, Teng KS, Lau SP. Graphene quantum dots from chemistry to applications. Materials Today Chemistry. 2018 Dec 1; 10:221-58. doi.org/10.1016/j.mtchem.2018.09.007.

5.   Bacon M, Bradley SJ, Nann T. Graphene quantum dots. Particle and Particle Systems Characterization. 2014 Apr;31(4):415-28. doi.org/10.1002/ppsc.201300252.

6.   Nordell KJ, Boatman EM, Lisensky GC. A safer, easier, faster synthesis for CdSe quantum dot nanocrystals. Journal of Chemical Education. 2005 Nov; 82(11):1697 doi.org/10.1021/ed082p1697.

7.   Chinnathambi S, Chen S, Ganesan S, Hanagata N. Silicon quantum dots for biological applications. Advanced Healthcare Materials. 2014 Jan;3(1):10-29. doi.org/10.1002/adhm.201300157.

8.   Morozova S, Alikina M, Vinogradov A, Pagliaro M. Silicon quantum dots: synthesis, encapsulation, and application in light-emitting diodes. Frontiers in Chemistry. 2020 Apr 7; 8:191. doi.org/10.3389/fchem.2020.00191.

9.   Yong KT, Wang Y, Roy I, Rui H, Swihart MT, Law WC, Kwak SK, Ye L, Liu J, Mahajan SD, Reynolds JL. Preparation of quantum dot/drug nanoparticle formulations for traceable targeted delivery and therapy. Theranostics. 2012; 2(7):681. doi.org/10.7150%2Fthno.

10.           Dey NS, Rao MB. Quantum dot: Novel carrier for drug delivery. Int. J. Res. Pharm. Biomed. Sci. 2011; 2(2):448-58. doi.org/10.2174/2211738507666190429113906.

11.           Abbasi E, Kafshdooz T, Bakhtiary M, Nikzamir N, Nikzamir N, Nikzamir M, Mohammadian M, Akbarzadeh A. Biomedical and biological applications of quantum dots. Artificial cells, Nanomedicine, and Biotechnology. 2016 Apr 2; 44(3):885-91. doi.org/10.3109/216914.

12.           Chen AA, Derfus AM, Khetani SR, Bhatia SN. Quantum dots to monitor RNAi delivery and improve gene silencing. Nucleic acids research. 2005 Jan 1; 33(22): e190-. doi.org/10.1093/nar/gni188.

13.           Zhang H. Quantum dot-A10 RNA aptamer-doxorubicin conjugate. doi.org/10.1002/anie.200602251.

14.           Matea CT, Mocan T, Tabaran F, Pop T, Mosteanu O, Puia C, Iancu C, Mocan L. Quantum dots in imaging, drug delivery and sensor applications. International Journal of Nanomedicine. 2017; 12:5421. doi.org/10.2147/IJN.S138624.

15.           Getz T, Qin J, Medintz IL, Delehanty JB, Susumu K, Dawson PE, Dawson G. Quantum dot‐mediated delivery of siRNA to inhibit sphingomyelinase activities in brain‐derived cells. Journal of Neurochemistry. 2016 Dec;139(5):872-85. doi.org/10.1111/jnc.13841.

16.           Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R, Farokhzad OC. Quantum dot− aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. doi.org/10.1021/nl.

17.           Schiffman JD, Balakrishna RG. Quantum dots as fluorescent probes: Synthesis, surface chemistry, energy transfer mechanisms, and applications. Sensors and Actuators B: Chemical. 2018 Apr 1; 258:1191-214. doi.org/10.1016/j.snb.2017.11.189.

 

 

Accepted on 01.04.2022           © RJPT All right reserved

Research J. Pharm. and Tech 2022; 15(12):5895-5902.